Catalyst for Payment Reform

@CPR4healthcare

Catalyst for Payment Reform (CPR) is working to change the way our nation pays for care, from volume to value.

Vrijeme pridruživanja: prosinac 2012.

Tweetovi

Blokirali ste korisnika/cu @CPR4healthcare

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CPR4healthcare

  1. If you're booked tomorrow, don't fret: the 2020 Aligned Sourcing toolkit is live and you can check it out now~

    Poništi
  2. CPR’s Aligned Sourcing Toolkit is a megaphone for purchasers, amplifying demands for transparency, payment & delivery reforms, accountability for quality, and lowering the cost of care. Want a deeper dive on what that means and how it works? Sign up:

    Poništi
  3. proslijedio/la je Tweet
    31. sij
    Poništi
  4. proslijedio/la je Tweet
    30. sij
    Poništi
  5. We're excited to hear all that will come out of the event Feb 12 in DC. Let's make 2020 the year of meaningfully addressing the affordability for patients and purchasers.

    Poništi
  6. Catalyst for Payment Reform was founded on the recognition that health care purchasers can wield power to change health care foundationally through aligned priorities and a unified set of demands. "Aligned Sourcing" references this mission.

    Poništi
  7. Paper mail does make a difference in insurance enrollment: For those uninsured throughout 2016, receiving a letter increased the probability of enrollment in 2017 coverage by 6.7 percent relative to those who did not receive a letter

    Poništi
  8. Our Scorecard measures not only how much $ flows through each payment reform method; it examines health care's performance on quality and affordability. While we saw increase in payment reform implementation, affordability trended in the wrong direction

    Poništi
  9. Thx . CPR is committed to using the power of purchasers to make the hc system more efficient, and we have a plan to make it happen.

    Poništi
  10. Groundbreaking research, available now! States are stepping up in a variety of ways to make health care more affordable, including through their state employee health benefit plans.

    Poništi
  11. Poništi
  12. remained flat in the low single digits, representing 1.6% of total dollars paid to providers in 2012 to 2% in 2017.

    Poništi
  13. Check out new scorecard grading states on their policies for addressing affordability. Glad to see our funded database on state laws impacting hc cost & quality helped in the development

    Poništi
  14. “What we’re seeing is employers using traditional data feeds differently. Customers are asking us to develop reference-based pricing or other new incentive payment models to drive benefit designs.” -- Bernadette Kelleher, High Line Health

    Poništi
  15. (2/2) In Nevada, "aggregated across reporting manufacturers, manufacturers of essential diabetes drugs earned $42 in profits for every $100 they spent on production and administrative costs".

    Poništi
  16. You can find payment reform implementation results from 2012, 2013, 2016, and 2017 all in one place! The Nat’l Scorecard on Commercial Payment Reform asks the hard questions about the payment reform movement.

    Poništi
  17. Purchasers have pushed health plans to change their approach to provider payment to improve value. The % of $$ flowing through value-oriented methods has increased, but there has been little to no change in the quality and affordability.

    Poništi
  18. Here's a round-up of the most popular free downloads from 2019 -- we might be biased, but there's some quality information in there!

    Poništi
  19. (3/3) "Increased transparency and more patient education regarding the out-of-pocket costs associated with specialty drugs should reduce the costs borne by consumers" reflecting that communication & value-based strategies can be targeted to lower spending

    Poništi
  20. (2/3) "Policymakers are becoming increasingly interested in outcome- or -based payments for high-cost specialty drugs, in which payment is determined by measuring clinical performance and cost-effectiveness relative to existing treatments"

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·